Printer Friendly

Concentric Analgesics Begins Clinical Trial of CA-008 for Post-Surgical Pain Following Bunionectomy.

M2 PHARMA-November 3, 2017-Concentric Analgesics Begins Clinical Trial of CA-008 for Post-Surgical Pain Following Bunionectomy

(C)2017 M2 COMMUNICATIONS

- US-based clinical-stage biopharmaceutical company Concentric Analgesics, Inc. has initiated a Phase 1b clinical trial with CA-008, a proprietary, water-soluble prodrug that converts into capsaicin, a potent TRPV-1 agonist, the company said.

Capsaicin, which has a long history of use as a topical analgesic, selectively and reversibly desensitizes pain-conducting nerve fibers (C-fiber nociceptors).

The Phase 1b study is a randomized, double-blind clinical trial, targeting approximately 32 patients undergoing bunionectomy. The goal of the single, ascending-dose trial is to examine the safety, tolerability, and pharmacokinetics of CA-008.

In addition to the company's post-surgical program, Concentric expects to complete a series of pre-clinical research studies by the end of 2017 for CA-011, its program in osteoarthritis.

Concentric Analgesic's lead investigational product candidates, CA-008 and CA-011, convert into capsaicin, a potent TRPV-1 agonist that evokes an initial neuronal excitation that is followed by a durable refractory state to provide long lasting analgesia.

Privately-held Concentric Analgesics is focused on discovering and developing novel, non-opioid therapeutics for the management of acute and chronic pain.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Nov 3, 2017
Words:198
Previous Article:Eleven Biotherapeutics Anticipates Proceeds of Underwritten Public Offering of USD 8m.
Next Article:Care.com Adds Dan Yoo to Board of Directors.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters